Zobrazeno 1 - 10
of 74
pro vyhledávání: '"Elizabeth I. Buchbinder"'
Autor:
Elizabeth I. Buchbinder, Amina Bougrine, Anita Giobbie-Hurder, Ai-Tram N. Bui, Nicole R. LeBoeuf
Publikováno v:
Journal of the American Academy of Dermatology. 87:403-406
Autor:
F. Stephen Hodi, Lisa Magarace, Jason L. Weirather, Brian J. Quattrochi, Nancy Bailey, Rizwan Haq, Michael Manos, Lynette M. Sholl, Patrick A. Ott, Elizabeth I. Buchbinder, Ryan C. Brennick, Anita Giobbie-Hurder, Peter Bowling, Benjamin Izar
Publikováno v:
Cancer Medicine, Vol 10, Iss 8, Pp 2627-2635 (2021)
Cancer Medicine
Cancer Medicine
Mucosal melanoma is a rare form of melanoma which arises from melanocytes in the mucosal membranes and can be effectively treated with immune checkpoint blockade (ICB). However, response rates in mucosal melanoma are lower than those observed for cut
Autor:
Brian R. Gastman, Ahmad A. Tarhini, Robert M. Conry, Pauline Funchain, Karl D. Lewis, Antoni Ribas, Sapna Pradyuman Patel, Hongli Li, Kenneth F. Grossmann, Magdalena Kovacsovics-Bankowski, Teresa M. Petrella, Elizabeth I. Buchbinder, Nageatte Ibrahim, Ragini R. Kudchadkar, James Moon, Douglas B. Johnson, Thach-Giao Truong, Larissa A. Korde, Michael V. Knopp, Kari Kendra, Elad Sharon, Scot Ebbinghaus, Bartosz Chmielowski, Vernon K. Sondak, John M. Kirkwood, Zeynep Eroglu, Nikhil I. Khushalani, Justine V. Cohen, Megan Othus, Krishna S Gunturu, Sama Ahsan
Publikováno v:
Cancer discovery, vol 12, iss 3
Cancer Discov
Cancer Discov
We conducted a randomized phase III trial to evaluate whether adjuvant pembrolizumab for one year (647 patients) improved recurrence-free survival (RFS) or overall survival (OS) in comparison with high-dose IFNα-2b for one year or ipilimumab for up
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be95c3ea01eedee0bb4c9a85fc5d89b2
https://escholarship.org/uc/item/8x51z8rb
https://escholarship.org/uc/item/8x51z8rb
Autor:
Patrick A. Ott, Osama E. Rahma, F. Stephen Hodi, Martha Brainard, Anita Giobbie-Hurder, Michael Manos, Joanna Baginska, Mariano Severgnini, Elizabeth I. Buchbinder, Rizwan Haq, Kevin Tyan
Publikováno v:
Cancer Immunology, Immunotherapy. 70:2209-2221
Immune checkpoint inhibitors (ICIs) often cause immune-related adverse events (irAEs), most of which are treated with corticosteroids despite evidence suggesting that corticosteroids may blunt antitumor efficacy. We sought to identify cytokine change
Autor:
Padmavathi Srivoleti, Shilpa Grover, Anita Giobbie-Hurder, Marta Braschi-Amirfarzan, Osama E. Rahma, Kenneth L. Kehl, Mark M. Awad, Alex B. Ruan, Elizabeth I. Buchbinder, F. Stephen Hodi, Patrick A. Ott, Amitabh Srivastava
Publikováno v:
JCO Oncology Practice. 16:e933-e942
PURPOSE: Enterocolitis is among the leading adverse events associated with immune checkpoint inhibitors (ICIs). There are limited retrospective data regarding the safety of ICIs in patients with inflammatory bowel disease (IBD; ulcerative colitis, Cr
Autor:
F. Stephen Hodi, Olga Pozdnyakova, Peter Miller, Christopher J. Gibson, Michael Manos, Adam S. Sperling, Elizabeth I. Buchbinder, Waihay J. Wong, Matthew S. Davids, Benjamin L. Ebert
Publikováno v:
Haematologica
Autor:
Michael Dougan, Elizabeth I. Buchbinder, Meredith Davis, Anita Giobbie-Hurder, William Martin-Doyle, Patrick A. Ott, Osama E. Rahma, Maria Gargano, F. Stephen Hodi, Shilpa Grover, Rawad Elias, Rizwan Haq, Taha Qazi, Kruti Vora, Steven M. Blum, Jeffrey J. Ishizuka, Kevin Tyan, Ryan J. Sullivan, Michael Manos, Lauren Eastman, Alex B. Ruan
Publikováno v:
Cancer
Background There is a lack of predictive markers informing on the risk of colitis in patients treated with immune checkpoint inhibitors (ICIs). The aim of this study was to identify potential factors associated with development of ICI colitis. Method
Autor:
Donald P. Lawrence, Kathleen L. Pfaff, Kristen Felt, Elizabeth I. Buchbinder, Anita Giobbie-Hurder, Patrick A. Ott, David F. McDermott, Evisa Gjini, Mariano Severgnini, Jacquelyn O. Wolff, Matthew Nazzaro, Ryan J. Sullivan, Rizwan Haq, Scott J. Rodig, F. Stephen Hodi
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
BackgroundAngiogenic factors promote the growth of tumor vasculature, modulate lymphocyte trafficking into tumors, and inhibit maturation of dendritic cells. We hypothesized that MEDI3617, a human IgG1 kappa monoclonal antibody directed against human
Autor:
George J. Weiner, Heather Kelley, Geoffrey T. Gibney, Montaser Shaheen, Mohammed M. Milhem, Theresa Medina, Yousef Zakharia, Elizabeth I. Buchbinder, Luping Zhao, Jason J. Luke, John M. Kirkwood, Adil Daud, Diwakar Davar, James E. Wooldridge, Antoni Ribas, Jiaxin Niu, Anthony J. Olszanski, Dmitri Bobilev, Takami Sato, Hong Liu, Bartosz Chmielowski, Kim Margolin, Inderjit Mehmi, Arthur M. Krieg
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundThere are limited therapeutic options for patients with progressive disease (PD) on or after PD-1–blocking antibody therapy. Vidutolimod (CMP-001) is a first-in-class, immunostimulatory virus-like particle containing a CpG-A Toll-like rec
Autor:
Elizabeth I. Buchbinder
Publikováno v:
Hematology/oncology clinics of North America. 35(1)
Immunotherapy with immune checkpoint inhibition has dramatically changed the treatment of melanoma. Immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated protein 4 and programmed cell death protein 1 are approved for the treatment